[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BalaBioResearch Avatar @BalaBioResearch BalaBio Research

BalaBio Research posts on X about $cort, $aard, $bmrn, $srpt the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXXX% finance XXXX% cryptocurrencies XXXX%

Social topic influence $cort 9.76%, $aard 9.76%, $bmrn 9.76%, $srpt 7.32%, $fold 7.32%, cort 4.88%, $inmb 4.88%, $abeo 4.88%, agencies 2.44%, $mreo XXXX%

Top accounts mentioned or mentioned by @lcccc333 @jeremyj0916 @yachmod @biotech2k1 @phoenix3million @capitalshipyard @dtklp1 @bae_wisnu89344

Top assets mentioned Corcept Therapeutics Inc. (CORT) BioMarin Pharmaceutical, Inc. (BMRN) Sarepta Therapeutics, Inc. (SRPT) Amicus Therapeutics, Inc (FOLD) SuperRare (RARE) Crinetics Pharmaceuticals, Inc. (CRNX) Synthetify (SNY) Xenon Pharmaceuticals Inc (XENE) Morgan Stanley (MS) Novartis AG (NVS)

Top Social Posts #

Top posts by engagements in the last XX hours

"$CORT Relacorilant shrunk XX% of microadenomas in the GRACE study with only XX% increasing in size after treatment (low sample size)"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-15 15:57:29 UTC XXX followers, XXX engagements

"$AARD The closer I look the murkier the science gets. I would stay away. Also if PW patients don't ever get full from eating why would a XX% gut restricted pill which is supposed to trick your body into thinking it's poison lower hunger These kids will search in trash to eat"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-23 17:32:31 UTC XXX followers, XXX engagements

"This senior official either doesn't actually know what the agencies plans are has bipolar disorder or is just lying to effect share price"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-24 19:59:14 UTC XXX followers, XX engagements

"$AARD Looking into ARD-101 feel free to DM if anyone has any perspective on the drug or MOA positive or negative"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-19 22:44:36 UTC XXX followers, XXX engagements

"Highest conviction long positions going into 2H25: (In order) $CORT* Corcept Therapeutics $ABEO* Abeona $RARE / $MREO* Ultragenyx/Mereo $SRPT Sarepta $CRNX Crinetics $FOLD* Amicus $BMRN BioMarin *research report posted"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-02 20:00:56 UTC XXX followers, 1134 engagements

"$CORT Q2 Earnings July XX they no longer have the excuse of pharmacy issues for revenue they need a big number to hit guidance don't be surprised if they miss due to lower WAC from their authorized generic. Anything under 220m revenue is a disappointment to me"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-24 20:36:04 UTC XXX followers, XX engagements

"$INMB they making sure those 2.5p expire worthless"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-18 19:40:59 UTC XXX followers, XXX engagements

"There's a massive difference between these X statements. You can't go from unanimous agreement the drug is gone forever to a small safety study to prove safety unless the trial laid out by the fda has an impossible endpoint. $SRPT"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-24 19:57:13 UTC XXX followers, XXX engagements

"$FOLD Hard to believe Amicus isn't an acquisition target at these prices. $SNY $BMRN make sense as possible targets though BMRN would need to leverage with debt. Unless they terribly botch their launches Amicus really should be an easy XX% to XXX% gain in the coming years"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-14 20:46:31 UTC XXX followers, XXX engagements

"$AARD would anyone be interested in a long form paper about ARD-101 and why I don't think the mechanism would work it would be much more in depth and longer than anything else I've posted. Unfortunately AARD has no options and a binary play would be very dangerous(-60% +300%)"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-24 17:06:34 UTC XXX followers, XXX engagements

"@jeremyj0916 Yep it brings me such strong anger that there are people who spend their time at companies such as these knowingly dosing patients with often net negative drugs and giving them false hope. These people get rich off retail investors while simultaneously hurting the weakest"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-14 22:13:59 UTC XXX followers, XXX engagements

"$AARD Selective TAS2R ligands can increase secretion of GLP-1 and PYY which affect satiety. ARD-101 is a broad TAS2R agonist with presumably a better safety profile to VYKAT XR. Theres very little clinical data available for ARD-101 so far. Source:"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-21 01:38:10 UTC XXX followers, XXX engagements

"@Biotech2k1 I think if a different company had the PMOs LGMD platform and the ARWR assets with no Elevidys it would be worth 4b at least. IMO the balance sheet fear is overblown. (I hate the PMOs but they sell so whatever)"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-17 20:17:31 UTC XXX followers, XX engagements

"$ABEO Q3 and Q4 earnings will be extremely important indicators of the commercial viability of Zevaskyn"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-21 19:13:36 UTC XXX followers, XXX engagements

"$CORT Relacorilant PR-Ovarian NDA I'm confident in approval due to stellar safety profile. Very interested to see the eventual pricing/other cancer indications"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-14 14:49:46 UTC XXX followers, XXX engagements

"$XENE At a first glance it looks to me like azetukalner is worth much more than Xenon's mc is showing. I'm not too knowledgeable in epilepsy so would to love to hear some opinions on it as the phase X data and MOA are very convincing to me"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-13 21:21:42 UTC XXX followers, XXX engagements

"$SRPT Best case scenario Ambulatory stays on market with black box and is submitting new protocol to FDA for non-ambulatory. Elevedys Q2: 282m PMOs Q2: 231m My january $30C gonna have a great day tomr :D"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-16 20:16:20 UTC XXX followers, XXX engagements

"$FOLD Morgan Stanley realized how grossly undervalued Amicus is today it always surprises me when the market reacts to analyst upgrades this strongly"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-17 13:36:54 UTC XXX followers, XXX engagements

"@Phoenix3million Original drop was due to liver worries on the atumelnant p2 data. I think its been so weak because there are no near term catalysts. FDA approval is basically a lock and there aren't any data readouts for awhile. It's just a long term double+ for me/ could be a novartis buy out"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-19 16:38:52 UTC XXX followers, XX engagements

"Thinking about writing a report on $BMRN lmk if you all would be interested My model has it conservatively at $14b MC (30% above closing price) and I have a lop of confidence in their management to make good M&A choices as possible upside. Inozyme was a steal"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-07-14 21:00:13 UTC XXX followers, XXX engagements

"$BMRN Biomarin under $60/share is an easy buy. EV at 3x sales is wild with their growth prospects and great management"
@BalaBioResearch Avatar @BalaBioResearch on X 2025-06-23 19:29:20 UTC XXX followers, XX engagements